Oral-intestinal vaccines against diseases caused by enteropathic organisms using antigens encapsulated within biodegradable-biocompatible microspheres
AssigneeThe United States of America as represented by the Secretary of the Army
InventorsDaniel L. Jarboe, Robert H. Reid, Edgar C. Boedeker, Frederick J. Cassels
Life of this patent
Estimating the term…
Abstract
This invention is directed to oral-intestinal vaccines and their use against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres.
Claims6
A method for inducing an immune response in mammals comprising administering a pharmaceutical composition comprising an antigenic synthetic peptide containing CFA/I pilus protein T-cell epitopes encapsulated within a biodegradable polymeric matrix comprising poly (DL-lactide-co-glycolide) having a relative ratio between the amount of lactide and glycolide components within the range of 48:52 to 58:42, wherein the CFA-I pilus protein T-cell epitopes consist of the amino acid sequence:
- (SEQ ID NO:
- 1) [4] (Asn-Ile-Thr-Val-Thr-Ala-Ser-Val-Asp-Pro),
- (SEQ ID NO:
- 11) (Gly-Asn-Tyr-Ser-Gly-Val-Val-Ser-Leu-Val), and mixtures thereof.
A composition for inducing an immune response in mammals comprising of an antigenic synthetic peptide containing CFA-1 pilus protein T-Cell epitopes encapsulated within a biodegradable-biocompatible poly(DL-lactide-co-glycolide) polymeric matrix, wherein said antigenic synthetic peptide is present in an amount of 0.1% to 1% by weight of said vaccine and said polymer is present in an amount of 99% to 99.9% by weight of said vaccine, wherein the CFA/I pilus protein T-cell epitopes consist of the amino acid sequence:
- (SEQ ID NO:
- 1) [4] (Asn-Ile-Thr-Val-Thr-Ala-Ser-Val-Asp-Pro),
- (SEQ ID NO:
- 11) (Gly-Asn-Tyr-Ser-Gly-Val-Val-Ser-Leu-Val), and mixtures thereof.
Dependencies are inferred from the claim text.